{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:20:16Z","timestamp":1794572416493,"version":"4.9.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy (IC). Some patients who are IC candidates instead receive ven\/aza. We retrospectively analyzed patients with newly diagnosed AML who received ven\/aza (n\u00a0=\u00a0143) or IC (n = 149) to compare outcomes, seek variables that could predict response to 1\u00a0therapy or the other, and ascertain whether treatment recommendations could be refined. The response rates were 76.9% for ven\/aza and 70.5% for IC. The median overall survival (OS) was 884 days for IC compared with 483 days for ven\/aza (P = .0020). A propensity-matched cohort was used to compare outcomes in the setting of equivalent baseline variables, and when matched for age, biological risk, and transplantation, the median OS was 705 days for IC compared with not reached for ven\/aza (P = .0667). Variables that favored response to ven\/aza over IC included older age, secondary AML, and RUNX1 mutations. AML M5 favored response to IC over ven\/aza. In the propensity-matched cohort analyzing OS, older age, adverse risk, and RUNX1 mutations favored ven\/aza over IC, whereas intermediate risk favored IC over ven\/aza. In conclusion, patients receiving IC have improved OS compared with those receiving ven\/aza. However, in a propensity-matched cohort of patients with equivalent baseline factors, there was a trend toward favorable OS for ven\/aza. Specific variables, such as RUNX1 mutations, reported here for the first time, can be identified that favor ven\/aza or IC, helping to guide treatment decisions for patients who may be eligible candidates for either therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005538","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T21:40:29Z","timestamp":1633729229000},"page":"5565-5573","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":182,"title":["Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6416-8855","authenticated-orcid":false,"given":"Evan M.","family":"Cherry","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[{"name":"Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-5019","authenticated-orcid":false,"given":"Maria","family":"Amaya","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McMahon","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Rosser","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schowinsky","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha","family":"Inguva","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Minhajuddin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Pei","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Stevens","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-7505","authenticated-orcid":false,"given":"Amanda","family":"Winters","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Gutman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"issue":"11","key":"2021122016304437200_B1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/ajh.25975","article-title":"Acute myeloid leukemia: 2021 update on risk-stratification and management","volume":"95","author":"Estey","year":"2020","journal-title":"Am J Hematol."},{"issue":"7","key":"2021122016304437200_B2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"issue":"1","key":"2021122016304437200_B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2021122016304437200_B4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"2021122016304437200_B5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol."},{"issue":"1","key":"2021122016304437200_B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2018-11-883454","article-title":"Venetoclax in AML: aiming for \u201cjust right\u201d","volume":"133","author":"Michaelis","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2021122016304437200_B7","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V14.3.7298","article-title":"The case for abandoning induction chemotherapy","volume":"14","author":"Pollyea","year":"2017","journal-title":"The Hematologist."},{"issue":"9","key":"2021122016304437200_B8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/ajh.25556","article-title":"Acute myeloid leukemia drug development in the post-venetoclax era","volume":"94","author":"Pollyea","year":"2019","journal-title":"Am J Hematol."},{"issue":"4","key":"2021122016304437200_B9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"issue":"4","key":"2021122016304437200_B10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"issue":"4","key":"2021122016304437200_B11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol."},{"issue":"6","key":"2021122016304437200_B12","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/10428194.2020.1864358","article-title":"The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia","volume":"62","author":"Abbott","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"19","key":"2021122016304437200_B13","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med."},{"issue":"1","key":"2021122016304437200_B14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate - a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol."},{"key":"2021122016304437200_B15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev.ps.46.020195.003021","article-title":"Multiple hypothesis testing","volume":"46","author":"Shaffer","year":"1995","journal-title":"Annu Rev Psychol."},{"issue":"26","key":"2021122016304437200_B16","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1182\/blood-2009-05-223784","article-title":"AML1\/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations","volume":"114","author":"Tang","year":"2009","journal-title":"Blood."},{"issue":"25","key":"2021122016304437200_B17","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2011.40.6652","article-title":"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures","volume":"30","author":"Mendler","year":"2012","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021122016304437200_B18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J Clin Oncol."},{"key":"2021122016304437200_B19","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2016.126","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia."},{"issue":"23","key":"2021122016304437200_B20","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med."},{"issue":"5","key":"2021122016304437200_B21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood."},{"issue":"6","key":"2021122016304437200_B22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11899-016-0348-8","article-title":"Definition of unfit for standard acute myeloid leukemia therapy","volume":"11","author":"Klepin","year":"2016","journal-title":"Curr Hematol Malig Rep."},{"issue":"1","key":"2021122016304437200_B23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/hematology.2020000087","article-title":"Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?","volume":"2020","author":"Chen","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"2021122016304437200_B24","author":"National Cancer Research Institute"},{"issue":"10","key":"2021122016304437200_B25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"issue":"21","key":"2021122016304437200_B26","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood.2019003357","article-title":"High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML","volume":"135","author":"Simon","year":"2020","journal-title":"Blood."},{"issue":"11","key":"2021122016304437200_B27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med."},{"issue":"7834","key":"2021122016304437200_B28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature."},{"issue":"1","key":"2021122016304437200_B29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.16235","article-title":"Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia","volume":"188","author":"Esparza","year":"2020","journal-title":"Br J Haematol."},{"issue":"9","key":"2021122016304437200_B30","doi-asserted-by":"crossref","first-page":"107688","DOI":"10.1016\/j.celrep.2020.107688","article-title":"Acute myeloid leukemia iPSCs reveal a role for RUNX1 in the maintenance of human leukemia stem cells","volume":"31","author":"Wesely","year":"2020","journal-title":"Cell Rep."},{"issue":"12","key":"2021122016304437200_B31","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med."},{"issue":"5","key":"2021122016304437200_B32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells [published correction appears in Cancer Cell. 2019;35(2):333-335]","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell."},{"issue":"4","key":"2021122016304437200_B33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood.2019898114","article-title":"Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II","volume":"134","author":"Jones","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2021122016304437200_B34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanmaki","year":"2020","journal-title":"Haematologica."},{"issue":"7","key":"2021122016304437200_B35","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"issue":"11","key":"2021122016304437200_B36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood."},{"issue":"12","key":"2021122016304437200_B37","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Can."},{"issue":"13","key":"2021122016304437200_B38","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood."},{"issue":"29","key":"2021122016304437200_B39","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021122016304437200_B40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41375-018-0275-x","article-title":"Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies","volume":"33","author":"Othus","year":"2019","journal-title":"Leukemia."},{"issue":"8","key":"2021122016304437200_B41","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/bloodadvances.2020001728","article-title":"Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"2021122016304437200_B42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am J Hematol."},{"issue":"4","key":"2021122016304437200_B43","doi-asserted-by":"crossref","first-page":"E108","DOI":"10.1002\/ajh.26112","article-title":"Acute myeloid leukemia after age 70 years: a retrospective comparison of survival following treatment with intensive versus HMA \u00b1 venetoclax chemotherapy","volume":"96","author":"Begna","year":"2021","journal-title":"Am J Hematol."},{"issue":"7","key":"2021122016304437200_B44","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv."},{"issue":"10","key":"2021122016304437200_B45","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"5","key":"2021122016304437200_B46","doi-asserted-by":"crossref","first-page":"E154","DOI":"10.1002\/ajh.26122","article-title":"Decitabine and venetoclax for IDH1\/2-mutated acute myeloid leukemia","volume":"96","author":"Venugopal","year":"2021","journal-title":"Am J Hematol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/24\/5565\/1853847\/advancesadv2021005538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/24\/5565\/1853847\/advancesadv2021005538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T15:38:01Z","timestamp":1725896281000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/24\/5565\/477176\/Venetoclax-and-azacitidine-compared-with-induction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":46,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005538","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]}}}